
Michaela Fontenay

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5025430/publications.pdf Version: 2024-02-01



MICHAELA FONTENAY

#	Article	IF	CITATIONS
1	The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/DendriticÂNeoplasms. Leukemia, 2022, 36, 1703-1719.	7.2	1,211
2	Elevated Calprotectin and Abnormal Myeloid Cell Subsets Discriminate Severe from Mild COVID-19. Cell, 2020, 182, 1401-1418.e18.	28.9	663
3	Prognostic Score Including Gene Mutations in Chronic Myelomonocytic Leukemia. Journal of Clinical Oncology, 2013, 31, 2428-2436.	1.6	462
4	Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes. Nature Medicine, 2020, 26, 1549-1556.	30.7	372
5	Molecular International Prognostic Scoring System for Myelodysplastic Syndromes. , 2022, 1, .		259
6	Clonal architecture of chronic myelomonocytic leukemias. Blood, 2013, 121, 2186-2198.	1.4	232
7	Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes. Blood, 2012, 119, 3211-3218.	1.4	220
8	Characteristic repartition of monocyte subsets as a diagnostic signature of chronic myelomonocytic leukemia. Blood, 2015, 125, 3618-3626.	1.4	197
9	TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups. Leukemia, 2019, 33, 1747-1758.	7.2	195
10	<i>SF3B1</i> -mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS. Blood, 2020, 136, 157-170.	1.4	195
11	Lenalidomide with or without erythropoietin in transfusion-dependent erythropoiesis-stimulating agent-refractory lower-risk MDS without 5q deletion. Leukemia, 2016, 30, 897-905.	7.2	109
12	Circulating Von Willebrand factor and high molecular weight multimers as markers of endothelial injury predict COVID-19 in-hospital mortality. Angiogenesis, 2021, 24, 505-517.	7.2	105
13	Mitochondria in hematopoiesis and hematological diseases. Oncogene, 2006, 25, 4757-4767.	5.9	85
14	Somatic Mutations in MDS Patients Are Associated with Clinical Features and Predict Prognosis Independent of the IPSS-R: Analysis of Combined Datasets from the International Working Group for Prognosis in MDS-Molecular Committee. Blood, 2015, 126, 907-907.	1.4	85
15	Flow cytometric detection of dyserythropoiesis: a sensitive and powerful diagnostic tool for myelodysplastic syndromes. Leukemia, 2013, 27, 1981-1987.	7.2	78
16	Prognostic Role of Gene Mutations in Chronic Myelomonocytic Leukemia Patients Treated With Hypomethylating Agents. EBioMedicine, 2018, 31, 174-181.	6.1	72
17	Biology and prognostic impact of clonal plasmacytoid dendritic cells in chronic myelomonocytic leukemia. Leukemia, 2019, 33, 2466-2480.	7.2	66
18	A variant erythroferrone disrupts iron homeostasis in <i>SF3B1</i> -mutated myelodysplastic syndrome. Science Translational Medicine, 2019, 11, .	12.4	55

MICHAELA FONTENAY

#	Article	IF	CITATIONS
19	Bone marrow niche-derived extracellular matrix-degrading enzymes influence the progression of B-cell acute lymphoblastic leukemia. Leukemia, 2020, 34, 1540-1552.	7.2	46
20	p53 activation during ribosome biogenesis regulates normal erythroid differentiation. Blood, 2021, 137, 89-102.	1.4	46
21	Assessment of ASC specks as a putative biomarker of pyroptosis in myelodysplastic syndromes: an observational cohort study. Lancet Haematology,the, 2018, 5, e393-e402.	4.6	44
22	Pairing MCLâ€1 inhibition with venetoclax improves therapeutic efficiency of BH3â€mimetics in AML. European Journal of Haematology, 2020, 105, 588-596.	2.2	38
23	Effect of lenalidomide treatment on clonal architecture of myelodysplastic syndromes without 5q deletion. Blood, 2016, 127, 749-760.	1.4	36
24	A common alternative splicing signature is associated with SF3B1 mutations in malignancies from different cell lineages. Leukemia, 2014, 28, 1355-1357.	7.2	30
25	Comprehensive proteomic analysis of murine terminal erythroid differentiation. Blood Advances, 2020, 4, 1464-1477.	5.2	29
26	Spontaneous and Fas-induced apoptosis of low-grade MDS erythroid precursors involves the endoplasmic reticulum. Leukemia, 2008, 22, 1864-1873.	7.2	27
27	Oxidized mitochondrial DNA released after inflammasome activation is a disease biomarker for myelodysplastic syndromes. Blood Advances, 2021, 5, 2216-2228.	5.2	24
28	Vitamin K antagonism impairs the bone marrow microenvironment and hematopoiesis. Blood, 2019, 134, 227-238.	1.4	23
29	Antileukemic activity of the VPS34-IN1 inhibitor in acute myeloid leukemia. Oncogenesis, 2020, 9, 94.	4.9	23
30	Architectural and functional heterogeneity of hematopoietic stem/progenitor cells in non-del(5q) myelodysplastic syndromes. Blood, 2017, 129, 484-496.	1.4	22
31	Lupus Anticoagulant Single Positivity During the Acute Phase of COVIDâ€19 Is Not Associated With Venous Thromboembolism or Inâ€Hospital Mortality. Arthritis and Rheumatology, 2021, 73, 1976-1985.	5.6	21
32	Bone marrow oxidative stress and specific antioxidant signatures in myelodysplastic syndromes. Blood Advances, 2019, 3, 4271-4279.	5.2	19
33	Clinical application of flow cytometry in patients with unexplained cytopenia and suspected myelodysplastic syndrome: A report of the European <scp>LeukemiaNet</scp> International <scp>MDSâ€Flow</scp> Cytometry Working Group. Cytometry Part B - Clinical Cytometry, 2023, 104, 77-86.	1.5	18
34	Dyserythropoiesis evaluated by the RED score and hepcidin:ferritin ratio predicts response to erythropoietin in lower-risk myelodysplastic syndromes. Haematologica, 2019, 104, 497-504.	3.5	17
35	Flow cytometric analysis of myelodysplasia: Preâ€analytical and technical issues—Recommendations from the European <scp>LeukemiaNet</scp> . Cytometry Part B - Clinical Cytometry, 2023, 104, 15-26.	1.5	16
36	ImmunoCluster provides a computational framework for the nonspecialist to profile high-dimensional cytometry data. ELife, 2021, 10, .	6.0	11

MICHAELA FONTENAY

#	Article	IF	CITATIONS
37	The fraction of CD117/câ€KITâ€expressing erythroid precursors predicts ESA response in lowâ€risk myelodysplastic syndromes. Cytometry Part B - Clinical Cytometry, 2019, 96, 215-222.	1.5	10
38	Lupus anticoagulant diagnosis in patients receiving direct oral FXa inhibitors at trough levels: A realâ€life study. International Journal of Laboratory Hematology, 2019, 41, 738-744.	1.3	9
39	Effect of rivaroxaban and dabigatran on platelet functions: in vitro study. Thrombosis Research, 2019, 183, 159-162.	1.7	9
40	Lenalidomide-mediated erythroid improvement in non-del(5q) myelodysplastic syndromes is associated with bone marrow immuno-remodeling. Leukemia, 2018, 32, 558-562.	7.2	6
41	The <i>CADM1</i> tumor suppressor gene is a major candidate gene in MDS with deletion of the long arm of chromosome 11. Blood Advances, 2022, 6, 386-398.	5.2	3
42	A Two-Gene Classifier for Chronic Myelomonocytic Leukemia (CMML) Patients Treated with Hypomethylating Agents (HMA): A Report By the GFM. Blood, 2015, 126, 2872-2872.	1.4	1
43	Translation defects in ribosomopathies. Current Opinion in Hematology, 2022, Publish Ahead of Print,	2.5	1
44	Metabolites of Tryptophan Catabolism Are Elevated in Sera of Patients with Myelodysplastic Syndromes and Inhibit Hematopoietic Progenitor Amplification. Blood, 2012, 120, 3843-3843.	1.4	0
45	Collapse of Ribosome Biogenesis Induces Rapid Erythroblast Differentiation. Blood, 2014, 124, 2671-2671.	1.4	0
46	Pegylated liposomal doxorubicin-induced palmar plantar erythrodyesthesia: Identification of risks factors Journal of Clinical Oncology, 2015, 33, e13569-e13569.	1.6	0
47	Gene Expression and Alternative Splicing Datasets Analyses of MDS with Ring Sideroblasts Highlight Alternative Branchpoint Usage in Genes Involved in Iron Metabolism and Erythropoiesis. Blood, 2016, 128, 1972-1972.	1.4	0
48	Comparison of the Molecular Spectrum of Lenalidomide-Treated Myelodysplastic Syndrome with and without Del(5q). Blood, 2016, 128, 3172-3172.	1.4	0
49	Proof of Principle for Mutations Monitoring Using Picoliter-Droplet Digital PCR on DNA and Living Cells: Application to Myelodysplastic Syndromes. Blood, 2016, 128, 5515-5515.	1.4	Ο
50	Architectural and Functional Heterogeneity of Hematopoietic Stem/Progenitor Cells in Non-Del(5q) Myelodysplastic Syndromes. Blood, 2016, 128, 3153-3153.	1.4	0